Evaluates risk of cancer and infections in liver transplant recipients with everolimus therapy, suggesting cost-effective outcomes.
Overall, CNI with EVR regimen in liver transplant remained cost-effective across co-occurring outcomes and perspectives, supporting risk-benefit balancing across cancer, posttransplant infection, and renal function.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: